【摘要】 目的研究重组人血管内皮抑制素(恩度)联合化疗治疗晚期非小细胞肺癌的临床疗效和毒性反应。方法 42例非小细胞肺癌中病理类型为:腺癌12例,鳞癌20例,腺鳞癌6例,其他类型4例,均为ⅢB～Ⅳ期患者。初治或复治,采用化疗联合恩度治疗,化疗采用常规方案。恩度联合一线化疗者35例,恩度联合二线化疗者5例,恩度联合三线及以上治疗者2例。结果全组42例有效率(CR+PR)为42.86%,疾病控制率为76.19%;中位TTP7.1个月。毒副反应主要为恶心、呕吐、骨髓抑制,轻度的心脏毒副反应,包括心悸、胸闷、早搏等。结论恩度联合化疗安全有效,耐受性好,毒副反应以Ⅰ～Ⅱ度为主,初治与复治均有效。更多还原

【Abstract】 Objective To summarized the result of containing endostar regimens in 42 patients with advanced non-small cell lung cancer(NSCLC),Initially appraises the clinical response,time to progress(TTP)and toxicity.Methods Forty-two patients with stage ⅢB-Ⅳ NSCLC,chemo-naive or relapse,after chemotherapy endostar 15mg/day,day1-14 every cycle.Pathology type:adenocarcinoma12 cases,squamous 20 cases,Adenosquamous carcinoma 6 cases,other 4 cases,first line treatment for 35 cases,second line 5 cases,more than third line treatment 2 cases.Results Response rate(CR+PR)was 42.86%,disease control rate was 76.19%,Only gradeⅠ/Ⅱ toxicities were observed at this combination.Conclusion Endostar combined chemotherapy was safe and well tolerated.Main toxicity is gradeⅠ/Ⅱ.It has benefit for first and second line combine treatment of NSCLC.Patients have survival benefits who response for the chemotherapy.更多还原